• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sanofi - American Depositary Shares (NQ:SNY)

50.16 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Sanofi - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
33 34 Next >
Why Thermo Fischer Stock Is Rising Wednesday
July 23, 2025
Thermo Fisher beat Q2 estimates, raised its 2025 guidance, and announced a CFO transition as easing tariffs support an improved outlook. 
Via Benzinga
Topics World Trade
Humana Moves To Cut Prior Authorization Delays, Streamline Care Approvals
July 22, 2025
Humana will cut prior authorizations, launch a gold card program, and speed up electronic approvals to improve care access and transparency by 2026. 
Via Benzinga
Trump Tariffs Forces AstraZeneca To Bring Substantial Pharmaceutical Production To US
July 22, 2025
AstraZeneca plans a $50 billion investment in U.S. facilities by 2030, including a Virginia plant focused on weight loss and metabolic drugs. 
Via Benzinga
Topics Government
Sanofi Expands Respiratory Vaccine Portfolio With UK Biotech Buy
July 22, 2025
Sanofi acquires Vicebio for $1.15 billion, adding a next-gen RSV-hMPV vaccine and ‘Molecular Clamp' tech to strengthen its respiratory vaccine pipeline. 
Via Benzinga
SANOFI-ADR (NASDAQ:SNY) - A Reliable Dividend Stock with Strong Fundamentals
June 05, 2025
Via Chartmill
GSK Seeks FDA Nod To Broaden RSV Vaccine For Younger At-Risk Adults
July 15, 2025
FDA accepts GSK's application to expand Arexvy vaccine use to at-risk adults aged 18–49, with a decision expected in the first half of 2026. 
Via Benzinga
Pfizer, Sanofi Find Relief As Delaware Top Court Rejects Zantac Expert Testimony
July 11, 2025
Delaware's top court reversed a ruling that allowed expert testimony in Zantac cancer lawsuits, citing improper legal standards by the trial judge. 
Via Benzinga
Topics Lawsuit
Dow Futures Edge Up As Trump Prepares More Tariff Letters: Freeport, UnitedHealth, Meta, Novo Nordisk, AstraZeneca Among Stocks In Focus
July 09, 2025
While Dow Jones futures edged up by 0.17% at the time of writing, the S&P 500 futures were up 0.15%. 
Via Stocktwits
Topics ETFs Government Stocks
Cogent's Chronic Immune Disorder Drug Has Strong Potential To Become A Blockbuster: Analyst
July 08, 2025
Cogent's bezuclastinib showed strong efficacy in a non-advanced SM trial, with a planned FDA submission expected by the end of 2025. 
Via Benzinga
Apogee Reverses Lower Despite Promise For Twice-Yearly Eczema Shot
July 07, 2025
Apogee Therapeutics shares crumbled Monday despite promising results for what could become a twice-yearly eczema shot. 
Via Investor's Business Daily
Regeneron's Lynozyfic Gains Accelerated FDA Approval For Heavily Pre-Treated Multiple Myeloma
July 03, 2025
FDA grants accelerated approval to Regeneron's Lynozyfic for relapsed multiple myeloma after strong results in a Phase 1/2 trial. 
Via Benzinga
Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?
June 28, 2025
Nektar Therapeutics soared 157% after Rezpeg succeeded in a Phase 2b eczema trial. Analysts forecast huge upside—here’s why there could be more gains ahead. 
Via MarketBeat
Why This Biotech Stock Just Doubled In A Single Day
June 26, 2025
Vor Biopharma shares surge 43% after licensing deal, $175M raise, and CEO transition. 
Via Benzinga
Why Is Nektar Therapeutics Stock Trading Higher On Wednesday?
June 25, 2025
Nektar's rezpegaldesleukin met key efficacy targets in a mid-stage eczema study, though analysts flagged safety and differentiation concerns. 
Via Benzinga
Gilead Bets On Kymera's CDK2 Molecular Glue Degrader For New Cancer Therapies
June 25, 2025
Kymera signs $750 million CDK2 drug deal with Gilead and earns $20 million from Sanofi as KT-485 advances toward clinical trials in inflammatory diseases. 
Via Benzinga
Why Is Cidara Therapeutics Stock Trading Higher On Monday?
June 23, 2025
Cidara's CD388 met key goals in a Phase 2b flu trial, showing strong efficacy and safety data, with FDA talks planned for advancing to Phase 3. 
Via Benzinga
FDA Approves Regeneron Sanofi Treatment For Rare Autoimmune Skin Disorder
June 20, 2025
Dupixent approved by FDA for bullous pemphigoid, offering a new option for adults with the rare autoimmune skin disease following positive trial results. 
Via Benzinga
Regeneron, Sanofi Say Their Inflammation Drug Approved By FDA For Rare Skin Disease Affecting Elderly, But Retail Stays Dull
June 20, 2025
The injection is now approved in the U.S. to treat eight distinct diseases with underlying type 2 inflammation. 
Via Stocktwits
Topics Supply Chain
Analysts Can't Get Enough of These Little-Known Biopharma Stocks
June 12, 2025
Three relatively unknown biopharma firms receive near-unanimous approval from analysts for their promising drug candidates in development. 
Via MarketBeat
Novavax's Experimental COVID-19-Influenza Combo Shot Shows Immune Response Among Older Adults In Phase 3 Trial
June 11, 2025
Novavax's combo and standalone flu vaccines showed strong immune responses and good safety in a Phase 3 trial of adults 65 and older. 
Via Benzinga
American Pharmacists Association Withholds Endorsement Of CDC's Revised COVID-19 Vaccine Guidance
June 10, 2025
The American Pharmacists Association announced Monday it will withhold endorsement of the CDC's updated immunization schedule. 
Via Benzinga
Vaccine Stocks Moderna, Pfizer Hit After A Surprise Blow From RFK Jr.
June 09, 2025
A CDC committee in charge of making vaccine recommendations was gutted Monday to make way for a new coalition. 
Via Investor's Business Daily
Topics Government
Beyfortus Output Tripled As Sanofi, AstraZeneca Scale Up For RSV Season
June 09, 2025
Sanofi boosts Beyfortus output for RSV season while Dupixent trial shows strong eczema relief in patients with skin of color. 
Via Benzinga
Applied Digital And Riot Platforms Are Among Top 10 Mid-Cap Gainers Last Week (Jun 2-Jun 6): Are The Others In Your Portfolio?
June 08, 2025
Via Benzinga
Deal Dispatch: TV Stations For Sale, This Buyer Wants Seconds On Pasta
June 06, 2025
Byron Allen dials out, Salesforce logs in. Here are the various deal announcements of the past week plus bankruptcy updates. 
Via Benzinga
Topics Bankruptcy
RFK Jr. Champions 'Medical Freedom' While Curtailing Access, Say Public Health Experts
June 06, 2025
U.S. Health Secretary Robert F. Kennedy Jr. has championed "medical freedom" while simultaneously limiting access to COVID-19 vaccines and restricting food stamp purchases, creating what public health... 
Via Benzinga
Kymera Therapeutics Says Atopic Dermatitis Potential Matches Sanofi/Regeneron's Blockbuster Dupixent In Early Biomarker Response
June 02, 2025
Kymera's KT-621 achieved rapid, deep STAT6 degradation and showed a strong safety profile in Phase 1, with the next trials planned through early 2026. 
Via Benzinga
Sanofi To Buy Blueprint Medicines For Up To $9.5B: Retail Sees More Acquisition Offers From European Pharma Companies
June 02, 2025
Sanofi will pay $129 per share in cash at closing, representing a 27% premium to Blueprint’s closing price on Friday of $101.35. 
Via Stocktwits
Moderna's New COVID Vaccine Secures FDA-Clearance For Seniors, At-Risk Individuals
June 02, 2025
Moderna's mNexspike COVID vaccine approved by FDA for older adults and at-risk groups after Phase 3 trial shows improved efficacy and safety profile. 
Via Benzinga
Sanofi Expands Rare Immunology Portfolio With Blueprint Buyout
June 02, 2025
Sanofi will acquire Blueprint Medicines for up to $9.5 billion, gaining Ayvakit and a promising immunology pipeline, including BLU-808 and elenestinib. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
33 34 Next >
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap